Catalyst Dossier · compiled by CeliA 🧫

TherapeuticsMD, Inc. (TXMD)

Pharmaceutical Preparations · market cap $9M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-15 (est.)Phase 2 · IG3018imp 7/10
2026-08-11Earningsimp 5/10
2026-09-15 (est.)Phase 2 · DPI-386 Nasal Gelimp 7/10
2026-10-15 (est.)Phase 2 · YL201 for Injectionimp 7/10
2026-11-30 (est.)Phase 2 · RNK08954imp 7/10
2026-12-15 (est.)Phase 2 · RNK08954-01imp 7/10
2027-05-01 (est.)Phase 2 · ALT-100 mAbimp 7/10

Pipeline

Asset	Phase	Indication
Dexycu	Phase 3	Inflammation
ETC-1002	Phase 3	Hypercholesterolemia
MSDC-0602K	Phase 2	Non-alcoholic Fatty Liver Disease
Collagenase clostridium histolyticum	Phase 2	Dupuytren's Disease
Human platelets	Phase 3	Cardiac Surgery
Pegtibatinase	Phase 3	Homocystinuria
Allo-QuadCAR01-T	Phase 2	Lymphoma Diffuse Large B-cell
188-0551 Solution	Phase 2	Plaque Psoriasis
IG3018	Phase 2	Hyperuricemia
YL201 for Injection	Phase 2	Advanced Solid Tumor
5 mg Serlopitant Tablets	Phase 2	Pruritus
3.2 mg intranasal carbetocin	Phase 3	Prader-Willi Syndrome
Halobetasol Propionate Lotion 0.05%	Phase 2	Psoriasis
XIAFLEX / XIAPEX	Phase 3	Dupuytren's Contracture
OPN-305	Phase 2	Myelodysplastic Syndrome
Gene Therapy product:vMCO-I	Phase 2	Retinitis Pigmentosa
GFH018	Phase 2	NSCLC, Stage III
Sevuparin	Phase 2	Sickle-Cell Disease
SRP1020	Phase 2	Advanced Solid Tumors
JP-1366 20mg	Phase 3	Erosive Esophagitis

Price & technical context

3-month

+5.5%

6-month

+28.7%

12-month

+86.7%

52-wk range

$1.04–$2.77

vs 50-day MA

+2.3%

vs 200-day MA

+12.9%

Realized vol

74.9%

Max drawdown

-65.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TXMD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.